All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Tapan M. Kadia, MD Anderson Cancer Center, Houston, US. We asked, How has acute myeloid leukemia treatment in elderly people changed in 2021?
How has AML treatment in elderly people changed in 2021?
Kadia begins by highlighting the treatment challenges for elderly patients, such as higher frequency of comorbidities, organ dysfunction, and frailty. He outlines therapies such as venetoclax and hypomethylating agents, which demonstrate a good safety profile. Finally, he discusses current studies that are further investigating the role of NGS and cytogenetic analysis in selecting treatment options and therapy combinations.
Andrew Wei | ISAL 2019 | Targeting cell survival in AML
Andrew Wei discusses venetoclax in the context of targeting cell survival in AML at the 17th annual Acute Leukemias Meeting
Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Tapan Kadia, MD Anderson Cancer Center,...
Subscribe to get the best content related to AML delivered to your inbox